GLP-1 medicines to improve heart, kidney, and metabolic health for people with HIV and type 2 diabetes
Official title: Real-World Effects of GLP-1 Receptor Agonists on Cardiovascular-Kidney–Metabolic Syndrome Progression and Lifetime Costs in People with HIV and Type 2 Diabetes
Funded at Boston University Medical Campus · NIH-11470780 · Data updated 2026-11-12
A real-world study will look at how GLP-1 receptor agonists affect heart and kidney health and lifetime costs for people living with HIV and type 2 diabetes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Boston University Medical Campus NIH-funded |
| Lab location | 1 site (Boston, United States) |
| Project start | August 15, 2026 |
| Project end | May 31, 2031 |
| Funding year | 2026 |
| Award (this year) | $837,125 |
| NIH project number | 1R01HL189487-01 |
| Project ID | NIH-11470780 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with HIV and type 2 diabetes who are treated with GLP-1 receptor agonists or are candidates for such therapy.
✕Less likely to help
Patients not using GLP-1 receptor agonists or not meeting the study criteria may not experience the observed benefits.
What this research studies
This project follows people who have HIV and type 2 diabetes to see if GLP-1 medications help with weight, blood sugar, and cardiovascular risks in real-life settings. It will use existing medical records and health data to understand outcomes and costs over time. The goal is to provide clearer guidance on when GLP-1 drugs might be most helpful for this population and how they compare to older diabetes therapies. Results could inform clinicians and patients about better options to reduce CKM complications and overall care costs.
Why it matters
Potential benefit: If successful, the study could lead to improved treatment choices and lower risk of heart and kidney problems for people with HIV and type 2 diabetes.
How similar studies have gone: Preliminary data in broader diabetes populations suggest GLP-1 receptor agonists improve weight and cardiovascular risk factors, supporting further study in people with HIV.
Where this research is happening
-
Boston University Medical Campus
Boston, United States Active
Researchers
- Principal investigator: Brennan, Alana Teresa — Boston University Medical Campus
- Study coordinator: Brennan, Alana Teresa
Related research
Other NIH-funded projects on the same topics.
-
Comparing bariatric (weight‑loss) surgery with GLP‑1 and SGLT‑2 diabetes medicines for people with obesity and type 2 diabetes
This project compares long-term benefits and safety of weight‑loss surgery versus GLP‑1 and SGLT‑2 diabetes medicines for adults who have obesity and type 2 diabetes.
-
Comparing the effectiveness and safety of surgery and medications for obesity and type 2 diabetes
This study is looking at how well metabolic surgery works compared to certain medications for treating obesity and type 2 diabetes, so that patients and doctors can better understand the best options for managing these conditions, especially for those who might not always get the best care.
-
How genes, environment, and gut bacteria affect type 2 diabetes and metabolic syndrome
This study is looking at how our genes, the environment we live in, and the bacteria in our gut all work together to affect the risk of developing type 2 diabetes and related health issues, using mice to see how changes in these areas can help us find better ways to treat diabetes.
-
Subtyping Core for Research on the Causes of Type 2 Diabetes (SCORE-T2D)
A new U01 grant from a university research team aims to understand why Type 2 diabetes differs so much between people and how to tailor prevention and treatment.
-
Michigan Diabetes Project: A Peer-Led Self-Management Program for Adults with Type 2 Diabetes
A peer-led self-management program for adults with type 2 diabetes is being tested to see if it improves blood sugar control and daily diabetes care.
-
Alzheimer’s and dementia risk in people with prediabetes or type 2 diabetes
This grant aims to understand why some older adults with prediabetes or type 2 diabetes develop memory problems or dementia.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.